Trials / Completed
CompletedNCT01925638
Effect of Ketoconazole on the Pharmacokinetics of Refametinib
An Open-label Study in Healthy Male Subjects to Assess the Effect of a Strong CYP3A4 Inhibitor, Ketoconazole, on the Pharmacokinetics of Refametinib
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to see if there is a difference between the way your body absorbs and distributes BAY86-9766 when given alone or in combination with ketoconazole, a drug which may affect how much BAY86-9766 is absorbed, distributed or eliminated from the body
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BAY86-9766 | |
| DRUG | Ketoconazole |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2013-08-20
- Last updated
- 2014-01-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01925638. Inclusion in this directory is not an endorsement.